Benefit of High-Dose Cytarabine-Based Consolidation Chemotherapy for Adults with Acute Myelogenous Leukemia

References

• Champlin R.E., Gale R.P. Acute myelogenous leukemia. Blood 1987; 69: 1551–1562
   PubMed Web of Science ®Google Scholar
• Mayer R.J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin. Oncol. 1987; 14: 384–396
   PubMed Web of Science ®Google Scholar
• Gale R.P., Foon K.A. Therapy of acute myelogenous leukemia. Semin. Hemalol. 1987; 24: 40–54
   PubMed Web of Science ®Google Scholar
• Cassileth P.A., Begg C.B., Bennett J.M., Bozdech M., Kahn S.B., Weiler C., Glick J.H. A randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia. Blood 1984; 63: 843–847
   PubMed Web of Science ®Google Scholar
• Champlin R., Gajewski J., Nimer S., Vollset S., Landaw E., Winston D., Schiller G., Ho W. Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J. Clin. Oncol. 1990; 8: 1199–1206
   PubMed Web of Science ®Google Scholar
• Schiller G., Gajewski J., Territo M., Nimer S., Lee M., Belin T., Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–2982
   PubMed Web of Science ®Google Scholar
• Mayer R.J., Schiffer C.A., Peterson B.A., Budman R., Silver R.T., Rai K.R., Cornwall C.G., Ellison R.R., Maguire M., Berg D.T., Davis R.B., McIntyre O.R., Frei E. Intensive post remission therapy in adults with acute nonlymphocytic leukemia using various schedules of ara-c: A progress report for the CALGB. Semin. Oncol. 1987; 14: 25–31
   PubMed Web of Science ®Google Scholar
• Preisler H.D., Raza A., Early A., Kirshner J., Brecher F.M., Freeman A., Rustman Y., Azarnia N., Priore R., Sandberg A., Block A.M., Browman G., Walker I., Benjer A., Miller K., D'Arrigo D., Doeblin T., Stein A., Bloom M., Logue G., Rustag P., Barcos M., Larson R., Joyce R. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J. Clin. Oncol. 1987; 5: 722–730
   PubMed Web of Science ®Google Scholar
• Cassileth P.A., Andersen J., Lazarus H.M., Colvin O.M., Bennett J.M., Stadtmauer E.A., Kaizer H., Weiner R.S., Edelstein M., Oken M.M. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J. Clin. Oncol. 1993; 11: 314–319
   PubMed Web of Science ®Google Scholar
• Linker C.A., Ries C.A., Damon L.E., Rugo H.S., Wolf J.L. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311–318
   PubMed Web of Science ®Google Scholar
• Forman S.J., Spruce W.E., Farbstein M.J., Wolff J.L., Scott E.P., Nademanee A.P., Fahey J.L., Hecht T., Zaia J.A., Krance R.A., Findley D.O., Blume K.G. Bone marrow ablation followed by allogeneic grafting during first complete remission of acute nonlymphocytic leukemia. Blood 1983; 61: 439–442
   PubMed Web of Science ®Google Scholar
• Curtis J.E., Messner H.A., Minden M.D., Minkin S., McCulloch E.A. High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: Contributions to outcome of clinical and laboratory attributes. J. Clin. Oncol. 1987; 5: 532–543
   PubMed Web of Science ®Google Scholar
• Bloomfield C.D., James G.W., Gottlieb A., Ramanan S.V., Blom J., Nissen N.I., Bank A., Ellison R.R., Kung F., Henry P., McIntyre O.R., Kaan S.K. Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Preisler H., Raza A., Larson R., Goldberg J., Tricot G., Carey M., Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leuk. Res. 1991; 15: 773–780
   PubMed Web of Science ®Google Scholar
• Bertino J.R. Improving the curability of acute leukemia: Pharmacologic approaches. II. Strategies to Cure Leukemia. Semin. Oncol. 1991; 28: 9–11
   Google Scholar
• Phillips G.L., Reece D.E., Shepherd J.D., Barnett M.J., Brown R.A., Frei-Lahr D.A., Klingemann H.-G., Bolwell B.J., Spinelli J.J., Herzig R.H., Herzig G.P. High-dose cytarabine and daunombicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–1435
   PubMed Web of Science ®Google Scholar
• Bodey G.P., Freireich E.J., Gehan E., McCredie K.G., Rodriguez V., Gutterman J., Burgess M.A. Late intensification therapy for acute leukemia in remission. JAMA 1976; 235: 1021–1025
   PubMed Web of Science ®Google Scholar
• Wolff S.N., Herzig R.H., Fay J.W., Phillips G.L., Lazarus H.M., Flexner J.M., Stein R.S., Greer J.P., Cooper B., Herzig G.P. High-dose cytarabine and daunombicin as consolidation therapy for acute myeloid leukemia in first remission. Long-term follow-up and results. J. Clin. Oncol. 1989; 7: 1260–1267
   PubMed Web of Science ®Google Scholar
• Wolff S.N., Marion J., Stein R.S., Flexner J.M., Lazarus H.M., Spitzer T.R., Phillips G.L., Herzig R.H., Herzig G.P. High-dose cytosine arabinoside and daunombicin as brief consolidation therapy for acute nonlymphocytic leukemia in first remission. A pilot study. Blood 1985; 65: 1407
   PubMed Web of Science ®Google Scholar
• Duffy T.P. How much is too much high dose cytosine arabinsode?. J. Clin. Oncol. 1985; 3: 601–603
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D.M., Daniel M.T., Flandrin G., Galton D. A. G., Gralnick H.R., Sultan C. Proposals for the classification of acute leukemias. Br. J. Haematol. 1977; 33: 451–485
   Web of Science ®Google Scholar
• Schiller G., Gajewski J., Nimer S., Territo M., Ho W., Lee M., Champlin R. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br. J. Haematol. 1992; 81: 170–177
   PubMed Web of Science ®Google Scholar
• Ellison R.R., Holland J.F., Weil M., Jacquillat C., Boiron M., Barnard J., Sawitsky A., Rosner F., Gussoff B., Silver R.T., Karanas A., Cuttner J., Spurr C.L., Hayes D.M., Blom J., Leone L.A., Haurani F., Kyle R., Hutchinson J.L., Forcier R.J., Moon J.H. Aarabinosyl cytosine. A useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Schiller G.J., Nimer S.D., Territo M.C., Ho W.G., Champlin R.E., Gajewski J.L. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J. Clin. Oncol. 1992; 10: 41–46
   PubMed Web of Science ®Google Scholar
• Miller A.B., Hoogstratten B., Staquet M., Winkler A. Reporting the results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Winston D.J., Ho W.G., Bruckner D.A., Champlin R.E. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann. Intern. Med. 1991; 115: 849–859
   PubMed Web of Science ®Google Scholar
• Dixon W.J. BMDP Programs in the Biomedical Sciences. University of California Press, Los Angeles, CA 1983
   Google Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Buchner T., Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). First-line chemotherapy. Blut 1990; 60: 61–67
   PubMedGoogle Scholar